Urinary N-Terminal Pro-Brain Natriuretic Peptide Predicts Acute Kidney Injury and Severe Disease in COVID-19.
Acute kidney injury
COVID-19
N-terminal pro-brain natriuretic peptide
Urinary biomarkers
Journal
Kidney & blood pressure research
ISSN: 1423-0143
Titre abrégé: Kidney Blood Press Res
Pays: Switzerland
ID NLM: 9610505
Informations de publication
Date de publication:
26 Jun 2023
26 Jun 2023
Historique:
received:
06
10
2022
accepted:
01
02
2023
medline:
27
6
2023
pubmed:
27
6
2023
entrez:
26
6
2023
Statut:
aheadofprint
Résumé
The ongoing COVID-19 pandemic is placing an extraordinary burden on our health care system with its limited resources. Accurate triage of patients is necessary to ensure medical care for those most severely affected. In this regard, biomarkers could contribute to risk evaluation. The aim of this prospective observational clinical study was to assess the relationship between urinary N-terminal pro-brain natriuretic peptide (NT-proBNP) and acute kidney injury (AKI) as well as severe disease in patients with COVID-19. 125 patients treated with an acute respiratory infection in the emergency department of the University Hospital Regensburg were analyzed. These patients were divided into a COVID-19 cohort (n = 91) and a cohort with infections not caused by severe acute respiratory syndrome-coronavirus-2 (n = 34). NT-proBNP was determined from serum and fresh urine samples collected in the emergency department. Clinical endpoints were the development of AKI and a composite one consisting of AKI, intensive care unit admission, and in-hospital death. 11 (12.1%) COVID-19 patients developed AKI during hospitalization, whereas 15 (16.5%) reached the composite endpoint. Urinary NT-proBNP was significantly elevated in COVID-19 patients who suffered AKI or reached the composite endpoint (each p < 0.005). In a multivariate regression analysis adjusted for age, chronic kidney disease, chronic heart failure, and arterial hypertension, urinary NT-proBNP was identified as independent predictor of AKI (p = 0.017, OR = 3.91 [CI: 1.28-11.97] per standard deviation [SD]), as well as of the composite endpoint (p = 0.026, OR 2.66 [CI: 1.13-6.28] per SD). Urinary NT-proBNP might help identify patients at risk for AKI and severe disease progression in COVID-19.
Identifiants
pubmed: 37364545
pii: 000529690
doi: 10.1159/000529690
pmc: PMC10308530
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
424-435Informations de copyright
© 2023 The Author(s). Published by S. Karger AG, Basel.
Références
Peptides. 2019 Jan;111:18-25
pubmed: 29859763
Nephrol Dial Transplant. 2009 Nov;24(11):3263-5
pubmed: 19736243
Ann Thorac Surg. 2021 Jan;111(1):191-198
pubmed: 32283087
Eur J Heart Fail. 2021 Mar;23(3):456-464
pubmed: 33421281
Eur J Heart Fail. 2010 Apr;12(4):331-7
pubmed: 20185430
Clin J Am Soc Nephrol. 2021 Apr 1;16(4):514-521
pubmed: 33661756
Cardiol Res Pract. 2021 Jul 8;2021:5537275
pubmed: 34306746
Congest Heart Fail. 2010 Sep-Oct;16(5):214-20
pubmed: 20887618
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Kidney Int. 2008 May;73(9):1008-16
pubmed: 18094679
Front Med (Lausanne). 2022 Jun 16;9:898513
pubmed: 35783618
Circulation. 2009 Jul 7;120(1):35-41
pubmed: 19546389
Lancet. 2019 Nov 23;394(10212):1949-1964
pubmed: 31777389
Eur J Heart Fail. 2004 Mar 15;6(3):257-60
pubmed: 14987573
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Eur J Heart Fail. 2006 Oct;8(6):621-7
pubmed: 16504578
BMJ. 2015 Oct 28;351:h5527
pubmed: 26511519
J Nephrol. 2021 Aug;34(4):1007-1018
pubmed: 34110585
Environ Health Prev Med. 2021 Apr 12;26(1):47
pubmed: 33845756
Nat Rev Nephrol. 2021 Nov;17(11):751-764
pubmed: 34226718
Crit Care. 2018 Aug 18;22(1):197
pubmed: 30119691
Lancet Digit Health. 2022 Oct;4(10):e727-e737
pubmed: 36057526
ESC Heart Fail. 2021 Jun;8(3):2293-2305
pubmed: 33822463